The Pathophysiological Role and Therapeutic Potential of Melatonin in Age-Related Macular Degeneration (AMD)

The Pathophysiological Role and Therapeutic Potential of Melatonin in Age-Related Macular Degeneration: A Comprehensive Meta-Synthesis

Introduction/Background Age-related macular degeneration (AMD) represents the foremost cause of irreversible central vision loss and legal blindness among the elderly in developed nations. The disease is conventionally divided into nonexudative (dry) AMD, defined by drusen accumulation, retinal pigment epithelium (RPE) dysfunction, and geographic atrophy, and exudative (wet) AMD, defined by pathological choroidal neovascularization (CNV) and vascular leakage. The pathogenesis of AMD is deeply multifactorial, driven by the convergence of chronic oxidative stress, mitochondrial dysfunction, lipofuscin accumulation, and progressive inflammation within the metabolically demanding RPE and photoreceptor layers.

Current therapeutic interventions, primarily anti-vascular endothelial growth factor (VEGF) injections, are restricted to managing late-stage wet AMD, leaving a critical unmet clinical need for early and dry AMD interventions. Recently, the focus of drug repurposing has shifted toward multi-target endogenous molecules capable of restoring cellular homeostasis. Melatonin (N-acetyl-5-methoxytryptamine), an evolutionarily conserved indoleamine neurohormone produced in the pineal gland and ocular tissues, possesses robust chronobiotic, antioxidant, anti-inflammatory, and anti-angiogenic properties. This comprehensive review synthesizes the current literature to elucidate the molecular mechanisms, preclinical evidence, clinical applications, and novel nanotechnological formulations of melatonin in the prevention and management of AMD.

Thematic Analysis Sections

Theme 1: Retinal Circadian Biology, Aging, and Systemic Risk Factors While melatonin is primarily secreted by the pineal gland to regulate the sleep-wake cycle, it is also synthesized locally within the mitochondria of the mammalian retina, including RPE and photoreceptor cells. Retinal melatonin signals through G-protein-coupled receptors (MT1 and MT2), locally modulating dopamine release, maintaining corneal hydration, and regulating the rhythmic shedding and phagocytosis of photoreceptor outer segment discs.

A critical theme across the literature is the age-dependent decline in melatonin synthesis, which significantly correlates with the onset of neurodegenerative ocular diseases. Observational studies show that patients with AMD exhibit substantially lower daytime and nocturnal serum melatonin, as well as reduced urinary 6-sulfatoxymelatonin levels, compared to age-matched healthy controls. Furthermore, epidemiological data indicate a strong clinical association between disrupted circadian rhythms (e.g., clinically diagnosed insomnia or night-shift work) and an elevated risk of AMD. Disruptions in chrononutrition and the circadian clock inherently accelerate retinal metabolic decline, positioning the age-related loss of melatonin as a direct driver of AMD pathogenesis.

Theme 2: Oxidative Stress, Mitochondrial Dysfunction, and Cellular Phase Separation The RPE is continuously exposed to intense light and high oxygen tension, resulting in the massive generation of reactive oxygen species (ROS) via the mitochondrial electron transport chain. Melatonin acts as a highly effective, mitochondria-targeted antioxidant, reaching high intracellular concentrations to scavenge free radicals directly. Beyond direct scavenging, melatonin modulates critical genetic pathways to enhance mitochondrial biogenesis and mitophagy. It activates the AMPK-PGC-1α-SIRT3 signaling axis, which subsequently upregulates endogenous antioxidant enzymes such as superoxide dismutase 2 (SOD2), heme oxygenase-1 (HO-1), and glutathione peroxidase.

Recent studies highlight melatonin's capacity to inhibit specific programmed cell death pathways in the RPE. Superoxide anions and blue light activate ferroptosis—an iron-dependent, lipid peroxidation-driven cell death mechanism—which directly contributes to dry AMD. Melatonin suppresses this ferroptotic cascade via the GSK-3β/Fyn-dependent Nrf2 nuclear translocation pathway and the preservation of GPX4. Furthermore, melatonin prevents RPE necroptosis and secondary cell death via the MT2/SERCA2/Ca2+ axis, inhibiting toxic mitochondrial calcium overload and mitochondrial permeability transition pore (mPTP) opening.

At a biophysical level, mitochondrial dysfunction in AMD triggers aberrant phase separation of biomolecular condensates due to ATP deficiency. The literature introduces a novel paradigm where melatonin regulates redox-sensitive phase separation of critical proteins (e.g., APOE2 and vimentin). By maintaining hydration and solubilizing pathological aggregates through π-π stacking, melatonin mitigates epithelial-to-mesenchymal transition and drusen nucleation. Furthermore, melatonin has been shown to upregulate hTERT expression, promoting telomerase activity to counter oxidative stress-induced telomere attrition in aging RPE cells.

Theme 3: Immunomodulation and Anti-Angiogenesis The progression of AMD is tightly linked to chronic inflammation and pathological angiogenesis. Melatonin downregulates pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) by suppressing the NLRP3 inflammasome and the NF-κB signaling pathway. In sodium iodate-induced retinal injury models, melatonin preserves retinal integrity by mediating immune homeostasis, specifically by recruiting regulatory T cells (Tregs) and modulating macrophage/microglia polarization.

In the context of exudative AMD, melatonin exhibits potent anti-angiogenic properties. It preserves the integrity of the inner blood-retinal barrier (iBRB) by downregulating hypoxia-inducible factor 1-alpha (HIF-1α) and VEGF expression under hypoxic conditions. Mechanistic studies explicitly demonstrate that melatonin directly binds to the VEGFR2 extracellular domain on endothelial progenitor cells (EPCs). This binding dose-dependently inhibits VEGF-induced EPC migration and angiogenesis via the c-Src/FAK, NF-κB, and AP-1 signaling pathways, subsequently reducing pathological PDGF-BB expression.

Theme 4: Clinical Efficacy, Drug Repurposing, and Nanoscale Delivery Systems Translation of melatonin from preclinical models to clinical application has gained considerable traction. In a landmark retrospective cohort study utilizing the TriNetX database encompassing over 120,000 patients, exogenous melatonin supplementation was associated with a striking 58% reduced risk of developing AMD, and a 57% decreased risk of progressing from dry to wet AMD. This aligns with an earlier prospective case series by Yi et al., which demonstrated that 3 mg of daily oral melatonin over 6 to 24 months stabilized visual acuity and minimized pathological fundus changes in the majority of AMD patients without significant side effects. Experimental models utilizing senescence-accelerated OXYS rats also confirm that melatonin significantly delays retinopathy manifestations.

However, translating these benefits via topical ocular administration is severely hindered by melatonin's poor aqueous solubility and low bioavailability (estimated at 15% orally due to first-pass metabolism). Advanced nanotechnological drug delivery systems have been developed to bypass these physiological barriers. Formulations utilizing poly(lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles (SLNs), Soluplus nanomicelles, and TAT-modified liposomes have been highly successful in improving transcorneal permeation, ensuring sustained release, and enhancing neuroprotective efficacy in vivo. For example, the combined formulation of melatonin and agomelatine in nanomicelles drastically improves distribution to the posterior eye segment, providing simultaneous intraocular pressure (IOP) reduction and robust neuroprotection for retinal ganglion cells.

Discussion/Gaps (Commonalities and Disagreements) Commonalities: A rigorous consensus exists across the literature regarding the multi-targeted efficacy of melatonin in mitigating AMD pathogenesis. There is unanimous agreement that melatonin effectively scavenges free radicals, prevents RPE cell apoptosis, preserves mitochondrial bioenergetics, and suppresses pathological VEGF signaling. Furthermore, multiple studies validate the utility of nanotechnology in overcoming melatonin's inherent pharmacokinetic limitations.

Disagreements and Variations: Despite overarching consensus, the literature diverges on the exact mechanistic dominance of melatonin's receptor-dependent versus receptor-independent functions. Some researchers argue that at physiological doses (10^-10 to 10^-8 M), melatonin relies strictly on MT1/MT2 receptor-mediated signaling cascades, whereas high pharmacological doses are required for direct, non-receptor-mediated radical scavenging. Furthermore, conflicting data exists regarding the specific mechanisms of immune modulation; while some sources suggest melatonin suppresses CNV by shifting macrophage polarization from the M2 to the M1 phenotype, others emphasize an M1 to M2 transition for optimal tissue repair and anti-inflammatory action. There is also ongoing debate over whether melatonin's neuroprotective properties in the retina are primary, or merely secondary to its localized hypotensive (IOP-lowering) effects.

Critical Gaps: A profound gap exists in the clinical translation of these findings. While large retrospective databases and small-scale uncontrolled case series suggest high efficacy, there is an absolute lack of large-scale, prospective, randomized placebo-controlled clinical trials establishing standardized oral or topical dosing regimens for AMD. Additionally, the long-term safety, pharmacokinetics, and human retinal accumulation of the novel nanocarriers (e.g., PLGA-PEG, nanomicelles, SLNs) remain completely uncharacterized in human subjects. Further empirical research is required to optimize chronotherapeutic administration (e.g., determining the precise nocturnal versus daytime dosing required to mimic physiological circadian peaks without disrupting endogenous rhythms).

Conclusion Age-related macular degeneration is a devastating, multi-pathway neurodegenerative disorder characterized by a severe bioenergetic crisis, oxidative stress, and chronic inflammation within the RPE-photoreceptor complex. This comprehensive literature review firmly establishes melatonin as a highly viable, pleiotropic therapeutic candidate capable of combating both nonexudative and exudative AMD. By functioning as a mitochondria-targeted antioxidant, an inhibitor of ferroptosis and necroptosis, and a potent suppressor of VEGF-induced angiogenesis, melatonin directly addresses the core pathophysiological mechanisms of AMD. While robust retrospective data and innovative nanotechnological delivery systems highlight the feasibility of melatonin-based therapies, the realization of its full clinical potential strictly depends on the execution of rigorous, large-scale prospective clinical trials to optimize targeted drug delivery and standardized chronotherapeutic dosing.

References

1. Lewis Luján LM, McCarty MF, Di Nicolantonio JJ, Gálvez Ruiz JC, Rosas-Burgos EC, Plascencia-Jatomea M, Iloki Assanga SB. Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration. Nutrients. 2022;14:1985.
2. Sun H, Li B, Gu Y, Li F, Di G, Chen P. Imbalanced mitochondrial homeostasis in ocular diseases: unique pathogenesis and targeted therapy. Experimental Eye Research. 2025;260:110632.
3. Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration. Expert Opinion on Drug Discovery. 2025;20(3):341.
4. Mimura T, Noma H. Title Oxidative Stress in Age-Related Macular Degeneration: From Molecular Mechanisms to Emerging Therapeutic Targets. Antioxidants. 2025;14:1251.
5. Mehrzadi S, Hemati K, Reiter RJ, Hosseinzadeh A. Mitochondrial dysfunction in age-related macular degeneration: melatonin as a potential treatment. Expert Opin Ther Targets. 2020;24:359–378.
6. Bilbao-Malavé V, González-Zamora J, de la Puente M, Layana AG, Recalde S, Fernandez-Robredo P, Hernandez M, Saenz de Viteri M. Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration. Antioxidants. 2021;10:1170.
7. Chhablani J, et al. Central serous chorioretinopathy randomized controlled trials. Eye. 2023;3312.
8. Felder-Schmittbuhl MP, Hicks D, Ribelayga CP, Tosini G. Melatonin in the mammalian retina: synthesis, mechanisms of action and neuroprotection. J Pineal Res. 2024;76:e12951.
9. Blasiak J, Reiter RJ, Kaarniranta K. Melatonin in Retinal Physiology and Pathology: The Case of Age-Related Macular Degeneration. Oxid Med Cell Longev. 2016;2016:6819736.
10. Zhang J, Zhou H, Cai Y, Yoshida S, Li Y, Zhou Y. Melatonin: Unveiling the functions and implications in ocular health. Pharmacological Research. 2024;205:107253.
11. Reiter RJ, Sharma R, Blasiak J, Rosales-Corral S, Loh D. Retinal pigment epithelium pathology in age-related macular degeneration: mitigation with melatonin. Front Med. 2026;13:1813015.
12. Alemán-González-Duhart D, Mandujano-Ferrer L. Chrononutrition and systemic health. Biochimie. 2026;14:38.
13. Schmid-Kubista KE, et al. Daytime levels of melatonin in patients with age-related macular degeneration. Acta Ophthalmologica. 2009;87(1):89-93.
14. Boccuni I, Fairless R. Retinal glutamate neurotransmission: from physiology to pathophysiological mechanisms of retinal ganglion cell degeneration. Life. 2022;12:0638.
15. Tsai DC, et al. The association between clinically diagnosed insomnia and age-related macular degeneration. Acta Ophthalmologica. 2020;98:1-10.
16. Rastmanesh R. Melatonin may play a causal role in the occurrence of age-related macular degeneration (AMD). Medical Hypotheses. 2011;76:79-85.
17. D'Angelo A, Vitiello L, Gagliardi V, Salerno G, De Pascale I, Coppola A, Abbinante G, Pellegrino A, Giannaccare G. The Role of Oral Supplementation for the Management of Age-Related Macular Degeneration: A Narrative Review. J Pers Med. 2024;14:653.
18. Sun J, Liu Y, Chen Z. Melatonin and retinal cell damage: molecular and biological functions. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398:3199-3212.
19. Nishi T, Saeki K, Miyata K, Yoshikawa T, Ueda T, Kurumatani N. Melatonin secretion and choroidal vascularity. Int Ophthalmol. 2025;45:472.
20. Romeo A, Kazsoki A, Musumeci T, Zelkó R. A Clinical, Pharmacological, and Formulation Evaluation of Melatonin in the Treatment of Ocular Disorders—A Systematic Review. Int J Mol Sci. 2024;25:3999.
21. Vladan B, Panfoli I. Melatonin and Abeta, Macular Degeneration and Alzheimers Disease: Same Disease, Different Outcomes? Medical Hypothesis, Discovery & Innovation Ophthalmology Journal. 2012;1(2):24-32.
22. Huang Y, Zhou Z. Superoxide Activates Ferroptosis in Retinal Pigment Epithelium Cells. Aging Cell. 2025;10:1111.
23. Zhi X, Lu H, Ma D, Liu J, Luo L, Wang L, Qin Y. Melatonin regulates photoreceptor cell ferroptosis on the progression of dry AMD via the GSK-3β/Fyn/Nrf2 pathway. BBA - Molecular Basis of Disease. 2023;1870:166969.
24. Ren C, Hu C, Hu M, Wu Y, Yang Y, Lu F. Melatonin protects RPE cells from necroptosis and NLRP3 activation via promoting SERCA2-related intracellular Ca2+ homeostasis. Phytomedicine. 2024;135:156088.
25. Chang CC, et al. Protective Effect of Melatonin against Oxidative Stress-Induced Apoptosis and Enhanced Autophagy in Human Retinal Pigment Epithelium Cells. Oxid Med Cell Longev. 2018;2018:9015765.
26. Ma C, Li H, Lu S, Li X. The Role and Therapeutic Potential of Melatonin in Degenerative Fundus Diseases: Diabetes Retinopathy and Age-Related Macular Degeneration. Drug Design, Development and Therapy. 2022;16:2329.
27. Ku LC, Sheu ML, Cheng HH, Lee CY, Tsai YC, Tsai CY, Lin KH, Lai LC, Lai DW. Melatonin protects retinal integrity through mediated immune homeostasis in the sodium iodate-induced mouse model of age-related macular degeneration. Biomedicine & Pharmacotherapy. 2023;161:114476.
28. Xu Y, Cui K, Li J, Tang X, Lin J, Lu X, Huang R, Yang B, Shi Y, Ye D. Melatonin attenuates choroidal neovascularization by regulating macrophage/microglia polarization via inhibition of RhoA/ROCK signaling pathway. J Pineal Res. 2020;69(1):e12660.
29. Diabetic macular edema. Unknown. Experimental Eye Research. 2021;260:110632.
30. Lin LW, et al. Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration. Cells. 2023;12:799.
31. Jeong H, Shaia JK, Markle JC, Talcott KE, Singh RP. Melatonin and Risk of Age-Related Macular Degeneration. JAMA Ophthalmol. 2024;142(7):648-654.
32. Yi C, Pan X, Yan H, Guo M, Pierpaoli W. Effects of Melatonin in Age-Related Macular Degeneration. Ann NY Acad Sci. 2006;1057:384-392.
33. Stefanova NA, Zhdankina AA, Fursova AZh, Kolosova NG. Potential of Melatonin for Prevention of Age-Related Macular Degeneration: Experimental Study. Advances in Gerontology. 2013;3(4):307-313.
34. Rusciano D, Russo C. The Therapeutic Trip of Melatonin Eye Drops: From the Ocular Surface to the Retina. Pharmaceuticals. 2024;17:441.
35. Rusciano D. A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies. Pharmaceuticals. 2025;18:883.
36. Diéguez HH, González Fleitas MF, Aranda ML, Calanni JS, Keller Sarmiento MI, Chianelli MS, Sande PH, Romeo HE, Rosenstein RE, Dorfman D. Melatonin protects the retina from experimental nonexudative age-related macular degeneration in mice. Journal of Pineal Research. 2020;68:e12643.
37. Kaufman M, Frehlich L. Blue-light filtering spectacle lenses. Cochrane Database of Systematic Reviews. 2024;10:1177.